Label-free sensing and atomic force spectroscopy for the characterization of protein-DNA and protein-protein interactions: Application to estrogen receptors

Journal of Molecular Recognition

Volumn 24, Issue 3, 2011, Pages 429-435

  Berthier, A ^a   Elie Caille, C ^a   Lesniewska, E ^b   Delage Mourroux, R ^a   Boireau, W ^a  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

DNA sensor; estrogen receptor; force spectroscopy

Indexed keywords

DNA; ESTROGEN RECEPTOR; PROTEIN;

ARTICLE; ATOMIC FORCE MICROSCOPY; GENETIC PROCEDURES; METABOLISM; METHODOLOGY; PROTEIN BINDING; SURFACE PLASMON RESONANCE;

BIOSENSING TECHNIQUES; DNA; MICROSCOPY, ATOMIC FORCE; PROTEIN BINDING; PROTEINS; RECEPTORS, ESTROGEN; SURFACE PLASMON RESONANCE;

EID: 79955087110     PISSN: 09523499     EISSN: 10991352     Source Type: Journal    
DOI: 10.1002/jmr.1106     Document Type: Article

References (44)

1. Ahn MR, Sheen YY., 1997. Antiestrogen interaction with estrogen receptors and additional antiestrogen binding sites in human breast cancer MCF-7 cells. Arch. Pharm. Res. 20 (6): 579-585. (Pubitemid 127697223)
2. Aoyagi S, Rouleau A, Boireau W., 2008. TOF-SIMS structural characterization of self-assembly monolayer of cytochrome b5 onto gold substrate. Appl. Surf. Sci. 255 (4): 1071-1074.
3. Arbuckle ND, Dauvois S, Parker MG., 1992. Effects of antioestrogens on the DNA binding activity of oestrogen receptors in vitro. Nucleic Acids Res. 20 (15): 3839-3844.
4. Asano K, Ono A, Hashimoto S, Inoue T, Kanno J., 2004. Screening of endocrine disrupting chemicals using a surface plasmon resonance sensor. Anal. Sci. 20 (4): 611-616.
5. Bergman Jungestrom M, Thompson LU, Dabrosin C., 2007. Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo. Clin. Cancer Res. 13 (3): 1061-1067. (Pubitemid 46340386)
6. Berthier A, Girard C, Grandvuillemin A, Muyard F, Skaltsounis AL, Jouvenot M, Delage-Mourroux R., 2007. Effect of 7-O-beta-D-glucopyranosylchrysin and its aglycone chrysin isolated from Podocytisus caramanicus on estrogen receptor alpha transcriptional activity. Planta Med. 73 (14): 1447-1451. (Pubitemid 350240500)
7. Boireau W, Bombard S, Sari MA, Pompon D., 2002. Bioengineering and characterization of DNA-protein assemblies floating on supported membranes. Biotechnol. Bioeng. 77 (2): 225-231. (Pubitemid 34072417)
8. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M., 1997. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 (6652): 753-758. (Pubitemid 27458965)
9. Cheskis BJ, Karathanasis S, Lyttle CR., 1997. Estrogen receptor ligands modulate its interaction with DNA. J. Biol. Chem. 272 (17): 11384-11391. (Pubitemid 27184143)
10. Diel P., 2002. Tissue-specific estrogenic response and molecular mechanisms. Toxicol. Lett. 127 (1-3): 217-224. (Pubitemid 34615513)
11. Feng J, Shi Z, Ye Z., 2008. Effects of metabolites of the lignans enterolactone and enterodiol on osteoblastic differentiation of MG-63 cells. Biol. Pharm. Bull. 31 (6): 1067-1070. (Pubitemid 351871152)
12. Fong CC, Wong MS, Fong WF, Yang M., 2002. Effect of hydrogel matrix on binding kinetics of protein-protein interactions on sensor surface. Anal. Chim. Acta 456 (2): 201-208. (Pubitemid 34241436)
13. Frederix F, Bonroy K, Laureyn W, Reekmans G, Campitelli A, Dehaen W, Maes G., 2003. Enhanced performance of an affinity biosensor interface based on mixed self-assembled monolayers of thiols on gold. Langmuir 19 (10): 4351-4357.
14. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC., 2002. Production and actions of estrogens. N. Engl. J. Med. 346 (5): 340-352.
15. Habauzit D, Armengaud J, Roig B, Chopineau J., 2008. Determination of estrogen presence in water by SPR using estrogen receptor dimerization. Anal. Bioanal. Chem. 390 (3): 873-883.
16. Ho PW, Garner CE, Ho JW, Leung KC, Chu AC, Kwok KH, Kung MH, Burka LT, Ramsden DB, Ho SL., 2008. Estrogenic phenol and catechol metabolites of PCBs modulate catechol-O-methyltransferase expression via the estrogen receptor: potential contribution to cancer risk. Curr. Drug Metab. 9 (4): 304-309. (Pubitemid 351836419)
17. Howell A., 2006. Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocrinol. Relat. Cancer 13 (3): 689-706. (Pubitemid 44763252)
18. Huang L, Reekmans G, Saerens D, Friedt JM, Frederix F, Francis L, Muyldermans S, Campitelli A, Van Hoof C., 2005. Prostate-specific antigen immunosensing based on mixed self-assembled monolayers, camel antibodies and colloidal gold enhanced sandwich assays. Biosens. Bioelectron. 21 (3): 483-490. (Pubitemid 41074936)
19. Inadera H., 2006. The immune system as a target for environmental chemicals: xenoestrogens and other compounds. Toxicol. Lett. 164 (3): 191-206. (Pubitemid 43766790)
20. Jacobsen DE, Samson MM, Schouw YT, Grobbee DE, Verhaar HJ., 2008. Efficacy of tibolone and raloxifene for the maintenance of skeletal muscle strength, bone mineral density, balance, body composition, cognitive function, mood/depression, anxiety and quality of life/well-being in late postmenopausal women ≥70 years: study design of a randomized, double-blind, double-dummy, placebo-controlled, single-center trial. Trials 9: 32, 1-9.
21. Klinge CM., 2000. Estrogen receptor interaction with co-activators and co-repressors. Steroids 65 (5): 227-251. (Pubitemid 30177344)
22. Klinge CM., 2001. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 29 (14): 2905-2919. (Pubitemid 32685217)
23. Kostelac D, Rechkemmer G, Briviba K., 2003. Phytoestrogens modulate binding response of estrogen receptors alpha and beta to the estrogen response element. J. Agric. Food Chem. 51 (26): 7632-7635.
24. Landgren MB, Bennink HJ, Helmond FA, Engelen S., 2002. Dose-response analysis of effects of tibolone on climacteric symptoms. BJOG 109 (10): 1109-1114. (Pubitemid 35287079)
25. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ., 1994. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J. Natl. Cancer Inst. 86 (20): 1534-1539. (Pubitemid 24330218)
26. Maggiolini M, Bonofiglio D, Marsico S, Panno ML, Cenni B, Picard D, Ando S., 2001. Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. Mol. Pharmacol. 60 (3): 595-602. (Pubitemid 32782656)
27. Mangeat T, Berthier A, Elie-Caille C, Perrin M, Boireau W, Pieralli C, Wacogne B., 2009. Gold/silica biochips: applications to surface plasmon resonnace and fluorescence quenching. Laser Phys. 19 (2): 252-258.
28. Martino S, Costantino J, McNabb M, Mershon J, Bryant K, Powles T, Secrest RJ., 2004a. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials. Oncologist 9 (2): 116-125. (Pubitemid 38452111)
29. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR., 2004b. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J. Natl. Cancer Inst. 96 (23): 1751-1761. (Pubitemid 39654569)
30. McCormack P, Sapunar F., 2008. Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer. Clin. Breast Cancer 8 (4): 347-351.
31. Merkel R, Nassoy P, Leung A, Ritchie K, Evans E., 1999. Energy landscapes of receptor-ligand bonds explored with dynamic force spectroscopy. Nature 397 (6714): 50-53. (Pubitemid 29038244)
32. Okubo T, Yokoyama Y, Kano K, Kano I., 2001. ER-dependent estrogenic activity of parabens assessed by proliferation of human breast cancer MCF-7 cells and expression of ERalpha and PR. Food Chem. Toxicol. 39 (12): 1225-1232. (Pubitemid 33030234)
33. O'Malley BW., 2005. A life-long search for the molecular pathways of steroid hormone action. Mol. Endocrinol. 19 (6): 1402-1411. (Pubitemid 41007053)
34. Power KA, Thompson LU., 2003. Ligand-induced regulation of ERalpha and ERbeta is indicative of human breast cancer cell proliferation. Breast Cancer Res. Treat. 81 (3): 209-221. (Pubitemid 37352458)
35. Rella R, Spadavecchia J, Manera MG, Siciliano P, Santino A, Mita G., 2004. Liquid phase SPR imaging experiments for biosensors applications. Biosens. Bioelectron. 20 (6): 1140-1148. (Pubitemid 39535572)
36. Saji S, Kuroi K., 2008. Application of selective estrogen receptor modulators for breast cancer treatment according to their intrinsic nature. Breast Cancer
37. Schuck P., 1996. Kinetics of ligand binding to receptor immobilized in a polymer matrix, as detected with an evanescent wave biosensor. I. A computer simulation of the influence of mass transport. Biophys. J. 70 (3): 1230-1249. (Pubitemid 26073037)
38. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL., 1998. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 (7): 927-937. (Pubitemid 29019045)
39. Soto AM, Vandenberg LN, Maffini MV, Sonnenschein C., 2008. Does breast cancer start in the womb ? Basic Clin. Pharmacol. Toxicol. 102 (2): 125-133. (Pubitemid 351143422)
40. Thompson LU., 1998. Experimental studies on lignans and cancer. Baillieres Clin. Endocrinol. Metab. 12 (4): 691-705. (Pubitemid 29261278)
41. Tiemann U., 2008. In vivo and in vitro effects of the organochlorine pesticides DDT, TCPM, methoxychlor, and lindane on the female reproductive tract of mammals: a review. Reprod. Toxicol. 25 (3): 316-326.
42. Vanparys C, Maras M, Lenjou M, Robbens J, Van Bockstaele D, Blust R, De Coen W., 2006. Flow cytometric cell cycle analysis allows for rapid screening of estrogenicity in MCF-7 breast cancer cells. Toxicol. in Vitro 20 (7): 1238-1248. (Pubitemid 44067385)
43. Wakeling AE, Dukes M, Bowler J., 1991. A potent specific pure antiestrogen with clinical potential. Cancer Res. 51 (15): 3867-3873.
44. Yarmush ML, Patankar DB, Yarmush DM., 1996. An analysis of transport resistances in the operation of BIAcore; implications for kinetic studies of biospecific interactions. Mol. Immunol. 33 (15): 1203-1214. (Pubitemid 27105329)